A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production

Experimental Hematology

Volumn 40, Issue 8, 2012, Pages 622-633

  Puthiyaveetil, Abdul Gafoor ^a,b   Heid, Bettina ^a,b   Reilly, Christopher M ^b,c   HogenEsch, Harm ^d   Caudell, David L ^a,b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^c EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CLASS SWITCH RECOMBINATION; CONTROLLED STUDY; FUSION GENE; GENETIC RECOMBINATION; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MOUSE; NHD13 GENE; NONHUMAN; NUP98 HOXD13 FUSION GENE; PRIORITY JOURNAL; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; IMMUNOGLOBULIN CLASS SWITCHING; LYMPHOPENIA; LYMPHOPOIESIS; MICE; MICE, TRANSGENIC; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION;

ESCHERICHIA COLI; MUS; MUS MUSCULUS;

EID: 84864012210     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.05.002     Document Type: Article

References (44)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Disperati P., Ichim C.V., Tkachuk D., Chun K., Schuh A.C., Wells R.A. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res 2006, 30:233-239.
3. Komrokji R., Bennett J.M. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep 2003, 2:179-185.
4. Heaney M.L., Golde D.W. Myelodysplasia. N Engl J Med 1999, 340:1649-1660.
5. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
6. Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999, 189:1399-1412.
7. Zheng X., Oancea C., Henschler R., Moore M.A., Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One 2009, 4:e7661.
8. Lam Q.L., Lo C.K., Zheng B.J., et al. Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice. Int Immunol 2007, 19:267-276.
9. Sternberg A., Killick S., Littlewood T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005, 106:2982-2991.
10. Amin H.M., Jilani I., Estey E.H., et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003, 102:1866-1868.
11. Nilsson L., Astrand-Grundstrom I., Arvidsson I., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96:2012-2021.
12. Hilbe W., Eisterer W., Schmid C., et al. Bone marrow lymphocyte subsets in myelodysplastic syndromes. J Clin Pathol 1994, 47:505-507.
13. Raghavachar A., Thiel E., Bartram C.R. Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 1987, 70:1079-1083.
14. Shi J., Shao Z.H., Liu H., et al. Transformation of myelodysplastic syndromes into acute myeloid leukemias. Chin Med J (Engl) 2004, 117:963-967.
15. Bonati A., Delia D., Starcich R. Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. Br J Haematol 1986, 64:487-491.
16. Labrie J.E., Sah A.P., Allman D.M., Cancro M.P., Gerstein R.M. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med 2004, 200:411-423.
17. Iwase O., Aizawa S., Kuriyama Y., Yaguchi M., Nakano M., Toyama K. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. Ann Hematol 1995, 71:293-299.
18. Fujii S., Shimizu K., Klimek V., Geller M.D., Nimer S.D., Dhodapkar M.V. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 2003, 122:617-622.
19. Srivannaboon K., Conley M.E., Coustan-Smith E., Wang W.C. Hypogammaglobulinemia and reduced numbers of B-cells in children with myelodysplastic syndrome. J Pediatr Hematol Oncol 2001, 23:122-125.
20. Tsuchida T., Sakane T., Ishikura H., Tsunematsu T. Impairment of lymphocyte function in patients with myelodysplastic syndrome and its correction by addition of Ca2+ ionophore and phorbol myristate acetate. Int J Hematol 1991, 54:505-513.
21. Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009, 94:449-451.
22. Raza-Egilmez S.Z., Jani-Sait S.N., Grossi M., Higgins M.J., Shows T.B., Aplan P.D. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998, 58:4269-4273.
23. Pineault N., Buske C., Feuring-Buske M., et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 2003, 101:4529-4538.
24. Slape C., Liu L.Y., Beachy S., Aplan P.D. Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood 2008, 112:2017-2019.
25. Choi C.W., Chung Y.J., Slape C., Aplan P.D. A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement. J Immunol 2009, 183:6227-6235.
26. Hodgkin P.D., Lee J.H., Lyons A.B. B cell differentiation and isotype switching is related to division cycle number. J Exp Med 1996, 184:277-281.
27. HogenEsch H., Janke S., Boggess D., Sundberg J.P. Absence of Peyer's patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J Immunol 1999, 162:3890-3896.
28. Meffre E., Casellas R., Nussenzweig M.C. Antibody regulation of B cell development. Nat Immunol 2000, 1:379-385.
29. Ward I.M., Reina-San-Martin B., Olaru A., et al. 53BP1 is required for class switch recombination. J Cell Biol 2004, 165:459-464.
30. Kracker S., Gardes P., Mazerolles F., Durandy A. Immunoglobulin class switch recombination deficiencies. Clin Immunol 2010, 135:193-203.
31. Rucci F., Notarangelo L.D., Fazeli A., et al. Homozygous DNA ligase IV R278H mutation in mice leads to leaky SCID and represents a model for human LIG4 syndrome. Proc Natl Acad Sci U S A 2010, 107:3024-3029.
32. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010, 184:4006-4016.
33. Smyth M.J., Teng M.W., Sharkey J., et al. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008, 68:3019-3025.
34. Herzenberg L.A., Tokuhisa T. Epitope-specific regulation. III. Induction of allotype-restricted suppression for IgG antibody responses to individual epitopes on complex antigens. Eur J Immunol 1982, 12:814-818.
35. Osborne D.P., Katz D.H. The allogeneic effect in inbred mice. I. Experimental conditions for the enhancement of hapten-specific secondary antibody responses by the graft-versus-host reaction. J Exp Med 1972, 136:439-454.
36. Yan Y., Park S.S., Janz S., Eckhardt L.A. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development. Genes Chromosomes Cancer 2007, 46:950-959.
37. Powers M.A., Forbes D.J., Dahlberg J.E., Lund E. The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways. J Cell Biol 1997, 136:241-250.
38. Capelson M., Liang Y., Schulte R., Mair W., Wagner U., Hetzer M.W. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 2010, 140:372-383.
39. Cross M.K., Powers M.A. Nup98 regulates bipolar spindle assembly through association with microtubules and opposition of MCAK. Mol Biol Cell 2011, 22:661-672.
40. Kalverda B., Pickersgill H., Shloma V.V., Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010, 140:360-371.
41. Laurell E., Beck K., Krupina K., et al. Phosphorylation of Nup98 by multiple kinases is crucial for NPC disassembly during mitotic entry. Cell 2011, 144:539-550.
42. Kohler A., Hurt E. Gene regulation by nucleoporins and links to cancer. Mol Cell 2010, 38:6-15.
43. Luo W., Liao W.J., Huang Y.T., et al. Cancer of the gastrointestinal tract results in a restricted T-cell repertoire dependent upon tumor differentiation. Cell Immunol 2011, 270:47-52.
44. Palmqvist L., Pineault N., Wasslavik C., Humphries R.K. Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes. PLoS One 2007, 2:e768.